R., M., P., P.H. and R., M.H. 2016. A prospective analysis of the cost-effectiveness of alfuzosin, tamsulosin and silodosin for 12 weeks in benign prostatic hyperplasia. International Journal of Basic & Clinical Pharmacology. 5, 6 (Dec. 2016), 2481–2487. DOI:https://doi.org/10.18203/2319-2003.ijbcp20164109.